The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Direct-to-Phase II SBIR Grant from the National Institutes of Health Entitled “Development of Topical Antiviral Agents for Treating Molluscum Contagiosum”
Doylestown, PA. March 21, 2016- FCCDC is pleased to announce that it was been awarded a Direct-to-Phase II SBIR grant from the National Institutes of Health entitled “Development of Topical Antiviral Agents for Treating Molluscum Contagiosum” (1R44AI125005-01), working together with Prof. Robert Ricciardi of the University of Pennsylvania.